0001225208-24-004692.txt : 20240401
0001225208-24-004692.hdr.sgml : 20240401
20240401185543
ACCESSION NUMBER: 0001225208-24-004692
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240401
FILED AS OF DATE: 20240401
DATE AS OF CHANGE: 20240401
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ullem Scott B.
CENTRAL INDEX KEY: 0001446989
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-15525
FILM NUMBER: 24811648
MAIL ADDRESS:
STREET 1: C/O EDWARDS LIFESCIENCES CORPORATION
STREET 2: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Edwards Lifesciences Corp
CENTRAL INDEX KEY: 0001099800
STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 364316614
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
BUSINESS PHONE: 9492502500
MAIL ADDRESS:
STREET 1: ONE EDWARDS WAY
CITY: IRVINE
STATE: CA
ZIP: 92614
FORMER COMPANY:
FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP.
DATE OF NAME CHANGE: 20090225
FORMER COMPANY:
FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP
DATE OF NAME CHANGE: 20000203
FORMER COMPANY:
FORMER CONFORMED NAME: CVG CONTROLLED INC
DATE OF NAME CHANGE: 19991126
4
1
doc4.xml
X0508
4
2024-04-01
0001099800
Edwards Lifesciences Corp
EW
0001446989
Ullem Scott B.
ONE EDWARDS WAY
IRVINE
CA
92614
1
CVP, Chief Financial Officer
1
Common Stock
2024-04-01
4
M
0
7255.0000
36.7500
A
26329.0000
D
Common Stock
2024-04-01
4
S
0
868.0000
95.5100
D
25461.0000
D
Common Stock
2024-04-01
4
S
0
6387.0000
94.8052
D
19074.0000
D
Common Stock
266318.0000
I
By Trust
Employee Stock Option (Right to Acquire)
36.7500
2024-04-01
4
M
0
7255.0000
0.0000
D
2018-05-11
2024-05-10
Common Stock
7255.0000
7250.0000
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 5, 2023.
This transaction was executed in multiple trades at prices ranging from $94.38 to $95.22. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
Linda J. Park, Attorney-in-Fact
2024-04-01